Earnings History Data for VAXART (VXRT) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

VAXART

Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The company's vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate risk of needle-stick injury. Its development programs are oral tablet vaccines designed to protect against norovirus, seasonal influenza and respiratory syncytial virus, as well as a therapeutic vaccine for human papillomavirus. Vaxart, Inc., formerly known as Aviragen Therapeutics, is based in South San Francisco, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
13-08-2025	AH		VXRT	VAXART	87.00	-0.07	-0.09	0.00	Vaxart GAAP EPS of -$0.07 beats by $0.02, revenue of $39.73M [8/13/2025 4:08 PM]	0.36	-0.01 (-2.54%)	0.0	0.0 (0.00%)	0.26 - 1.07	277,993	2,380,000	0
Vaxart GAAP EPS of -$0.07 beats by $0.02, revenue of $39.73M [8/13/2025 4:08 PM] Vaxart outlines accelerated COVID-19 trial data timeline and plans norovirus Phase IIb pending funding [8/13/2025 9:02 PM]
13-05-2025	AH		VXRT	Vaxart, Inc.	95.65	-0.07	-0.06	-0.14	Vaxart GAAP EPS of -$0.07 in-line, revenue of $20.9M [5/13/2025 4:14 PM]	0.4011	-0.01 (-3.47%)	0.41	-0.01 (-1.44%)	0.29 - 1.07	1,247,927	1,690,000	13,079
Vaxart GAAP EPS of -$0.07 in-line, revenue of $20.9M [5/13/2025 4:14 PM] Vaxart appoints Jeroen Grasman as chief financial officer [5/13/2025 4:12 PM] Vaxart signals cash runway into Q1 2026 while advancing COVID-19 and norovirus vaccine programs [5/13/2025 8:43 PM] Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results [2025-05-13 04:05PM] Vaxart Appoints Jeroen Grasman as Chief Financial Officer [2025-05-13 04:01PM] Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement [May-12-25 08:00AM]
20-03-2025	AH		VXRT	Vaxart, Inc.	130.89	-0.05	-0.10	-0.12	Vaxart GAAP EPS of -$0.33 beats by $0.06, revenue of $28.7M misses by $5.6M [3/20/2025 4:02 PM]	0.5085	-0.06 (-10.43%)	0.54	-0.03 (-4.53%)	0.45 - 1.41	2,126,565	1,630,000	53,314
Vaxart GAAP EPS of -$0.33 beats by $0.06, revenue of $28.7M misses by $5.6M [3/20/2025 4:02 PM] Here are the major earnings after the close today [2025-03-20 10:00AM]
13-11-2024	AH		VXRT	Vaxart, Inc.	157.80	-0.06	-0.10	-0.11	Vaxart GAAP EPS of -$0.06 beats by $0.04, revenue of $4.93M beats by $3.43M [11/13/2024 4:03 PM]	0.6307	-0.08 (-11.70%)	0.69	-0.02 (-2.70%)	0.52 - 1.54	2,435,423	1,410,000	15,110
Vaxart GAAP EPS of -$0.06 beats by $0.04, revenue of $4.93M beats by $3.43M [11/13/2024 4:03 PM] Earnings Snapshot: Vaxart beats Q3 estimates; records R&D expenses of $15.1M [11/13/2024 5:19 PM] Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results [2024-11-13 04:01PM]
08-08-2024	AH		VXRT	Vaxart, Inc.	107.45	-0.09	0.03	-0.16	Vaxart GAAP EPS of -$0.09 misses by $0.06, revenue of $6.4M misses by $15.57M [8/8/2024 4:02 PM]	0.5817	-0.05 (-7.68%)	0.62	-0.01 (-1.60%)	0.52 - 1.54	1,824,682	1,550,000	20,898
Vaxart GAAP EPS of -$0.09 misses by $0.06, revenue of $6.4M misses by $15.57M [8/8/2024 4:02 PM]
13-05-2024	AH		VXRT	Vaxart, Inc.	127.20	-0.14	-0.16	-0.19	Vaxart GAAP EPS of -$0.14 in-line, revenue of $2.18M beats by $1.38M [5/13/2024 4:03 PM]	0.8690	0.05 (5.98%)	0.90	0.08 (10.28%)	0.53 - 1.59	2,105,007	1,410,000	178,945
Vaxart up 10% on quarterly revenue beat, eyes COVID oral vaccine trial start in Q2 [5/13/2024 5:01 PM] Vaxart GAAP EPS of -$0.14 in-line, revenue of $2.18M beats by $1.38M [5/13/2024 4:03 PM]
14-03-2024	AH		VXRT	Vaxart, Inc.	173.32	-0.12	-0.14	-0.18	Vaxart GAAP EPS of -$0.57 beats by $0.02, revenue of $7.4M beats by $2.19M [3/14/2024 4:15 PM]	1.10	0.0 (0.00%)	1.10	0.0 (0.00%)	0.53 - 1.59	1,540,686	1,390,000	3,263
Vaxart GAAP EPS of -$0.57 beats by $0.02, revenue of $7.4M beats by $2.19M [3/14/2024 4:15 PM]
02-11-2023	AH		VXRT	Vaxart, Inc.	100.39	-0.11	-0.18	-0.23	Vaxart GAAP EPS of -$0.11 beats by $0.07, revenue of $2.1M beats by $2M [11/2/2023 4:09 PM]	0.70	0.03 (5.09%)	0.67	0.0 (0.42%)	0.56 - 1.73	1,146,452	730,000	20,544
Vaxart GAAP EPS of -$0.11 beats by $0.07, revenue of $2.1M beats by $2M [11/2/2023 4:09 PM]
03-08-2023	AH		VXRT	Vaxart, Inc.	105.73	-0.16	-0.19	-0.23	Vaxart GAAP EPS of -$0.16 beats by $0.02, revenue of $1.36M beats by $1.28M [8/3/2023 4:06 PM]	0.7615	0.01 (1.53%)	0.79	0.04 (5.20%)	0.56 - 4.61	692,366	910,000	2,390
Vaxart GAAP EPS of -$0.16 beats by $0.02, revenue of $1.36M beats by $1.28M [8/3/2023 4:06 PM]
04-05-2023	AH	4:00 PM ET (May 4)	VXRT	Vaxart, Inc.	112.04	-0.19	-0.19	-0.20	Vaxart GAAP EPS of -$0.19 in-line, revenue of $0.67M misses by $0.13M [5/4/2023 4:27 PM]	0.8681	0.01 (0.94%)	0.82	-0.04 (-4.65%)	0.56 - 4.61	590,108	880,000	21,845
Vaxart GAAP EPS of -$0.19 in-line, revenue of $0.67M misses by $0.13M [5/4/2023 4:27 PM]
15-03-2023	AH	4:00 PM ET (Mar 15)	VXRT	Vaxart, Inc.	120.11	-0.18	-0.22	-0.17	Vaxart GAAP EPS of -$0.84 misses by $0.01 [3/15/2023 4:02 PM]	0.7838	0.02 (3.12%)	0.73	-0.03 (-3.30%)	0.73 - 5.43	974,593	1,740,000	12,062
Vaxart GAAP EPS of -$0.84 misses by $0.01 [3/15/2023 4:02 PM] Vaxart to delay COVID-19 clinical trials in portfolio reorganization [3/15/2023 4:33 PM]
08-11-2022	AH	4:00 PM ET (Nov 8)	VXRT	Vaxart, Inc.	187.23	-0.23	-0.24	-0.14	Vaxart GAAP EPS of -$0.23 beats by $0.01 [11/8/2022 4:03 PM]	1.26	-0.12 (-8.99%)	1.41	0.02 (1.55%)	1.26 - 8.13	3,563,785	3,000,000	10,922
Vaxart GAAP EPS of -$0.23 beats by $0.01 [11/8/2022 4:03 PM] Vaxart stock slips more than 8% as Q3 expenses jump, cash position deteriorates [11/9/2022 2:46 PM]
08-08-2022	AH	5:45 PM ET (Aug 8)	VXRT	Vaxart, Inc.	472.91	-0.23	-0.21	-0.13	Vaxart GAAP EPS of -$0.23, revenue of $0M [8/8/2022 4:21 PM]	4.22	-0.07 (-1.63%)	3.93	-0.36 (-8.39%)	2.49 - 10.33	2,972,417	2,450,000	46,480
Vaxart GAAP EPS of -$0.23, revenue of $0M [8/8/2022 4:21 PM]
04-11-2021	AH		VXRT	VAXART	903.00	-0.14	-0.15	0.00	Vaxart EPS in-line, beats on revenue [11/4/2021 5:22 PM]	6.69	-0.20 (-2.90%)	6.79	-0.10 (-1.45%)	3.50 - 24.90	5,034,077	3,120,000	182,371
Vaxart EPS in-line, beats on revenue [11/4/2021 5:22 PM] Vaxart Provides Business Update and Reports Third Quarter 2021 Financial Results [Nov-04-21 04:01PM] 5 Biotech Stocks With 105% to 386% Upside, According to Wall Street [Nov-03-21 05:51AM] Earnings Preview: VAXART, INC. (VXRT) Q3 Earnings Expected to Decline [Nov-04-21 03:01PM] VAXART, INC. (VXRT) Reports Q3 Loss, Lags Revenue Estimates [Nov-04-21 05:25PM] 3 COVID Pill Stocks That Might Be Game-Changers [Nov-05-21 06:25AM]
03-05-2021	PM		VXRT	Vaxart, Inc.	1,085	-0.14	-0.10	0.00	Vaxart EPS misses by $0.04, misses on revenue [5/3/2021 8:19 AM]	8.01	-2.77 (-25.70%)	9.96	-0.82 (-7.61%)	2.23 - 24.90	77,370,949	53,570,000	12,045,385
Vaxart EPS misses by $0.04, misses on revenue [5/3/2021 8:19 AM] Vaxart shares slide after first-quarter earnings miss [5/3/2021 8:37 AM] Vaxart Reports First Quarter 2021 Financial Results and Provides Business Update [May-03-21 08:00AM] Vaxart Jumps on Optimism of Oral COVID Variant-Fighting Vaccine [May-03-21 03:42AM] Why Vaxart Stock Is Soaring Today [Apr-30-21 06:17PM] Vaxart Falls Ahead of Oral COVID Variant-Fighting Vaccine Results [May-03-21 05:42AM] VAXART, INC. (VXRT) Reports Q1 Loss, Misses Revenue Estimates [May-03-21 09:15AM] Earning roundup: Estée Lauder sales jump 16%, Vaxart COVID-19 vaccine trial start delayed [May-03-21 11:35AM] Vaxart Stock Plummets On Growing Losses As Investors Eye Covid Pill [May-03-21 02:10PM] New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses [May-03-21 05:06PM]
12-05-2020	AH		VXRT	Vaxart, Inc.	211.12	-0.02	-0.04	-0.18	Vaxart EPS beats by $0.02, beats on revenue [5/12/2020 4:25 PM]	2.79	-0.22 (-7.31%)	2.85	0.06 (2.15%)	0.25 - 4.12	6,224,280	5,742,627	59,889